PMC:7534795 / 6063-6240 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T41271","span":{"begin":21,"end":25},"obj":"Body_part"},{"id":"T45585","span":{"begin":46,"end":53},"obj":"Body_part"},{"id":"T90573","span":{"begin":101,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A58565","pred":"fma_id","subj":"T41271","obj":"http://purl.org/sig/ont/fma/fma86583"},{"id":"A77219","pred":"fma_id","subj":"T45585","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A37735","pred":"fma_id","subj":"T90573","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"Anakinra, a modified IL-1 receptor antagonist protein, is suggested to have therapeutic potential in cytokine storm, given its effectiveness on patient survival in severe sepsis"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T66694","span":{"begin":10,"end":11},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Anakinra, a modified IL-1 receptor antagonist protein, is suggested to have therapeutic potential in cytokine storm, given its effectiveness on patient survival in severe sepsis"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T53","span":{"begin":21,"end":23},"obj":"Chemical"},{"id":"T55","span":{"begin":35,"end":45},"obj":"Chemical"},{"id":"T56","span":{"begin":46,"end":53},"obj":"Chemical"}],"attributes":[{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A54","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A55","pred":"chebi_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A56","pred":"chebi_id","subj":"T56","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Anakinra, a modified IL-1 receptor antagonist protein, is suggested to have therapeutic potential in cytokine storm, given its effectiveness on patient survival in severe sepsis"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T23","span":{"begin":101,"end":115},"obj":"Phenotype"},{"id":"T24","span":{"begin":171,"end":177},"obj":"Phenotype"}],"attributes":[{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0033041"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0100806"}],"text":"Anakinra, a modified IL-1 receptor antagonist protein, is suggested to have therapeutic potential in cytokine storm, given its effectiveness on patient survival in severe sepsis"}

{"project":"LitCovid-PubTator","denotations":[{"id":"165","span":{"begin":21,"end":45},"obj":"Gene"},{"id":"178","span":{"begin":144,"end":151},"obj":"Species"},{"id":"193","span":{"begin":171,"end":177},"obj":"Disease"}],"attributes":[{"id":"A165","pred":"tao:has_database_id","subj":"165","obj":"Gene:3557"},{"id":"A178","pred":"tao:has_database_id","subj":"178","obj":"Tax:9606"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:D018805"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Anakinra, a modified IL-1 receptor antagonist protein, is suggested to have therapeutic potential in cytokine storm, given its effectiveness on patient survival in severe sepsis"}